Electrovaya Announces Results of Annual Meeting of Shareholders
MNP LLP, were re-appointed as the auditors of the Company.
Additional details are included in the report of voting results filed under the Company's profile on SEDAR at www.sedar.com.
About Electrovaya Inc.
Electrovaya Inc. (NASDAQ:ELVA) (TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries and battery systems for energy storage and heavy duty electric vehicles based on its Infinity Battery Technology Platform. This technology offers enhanced safety and industry leading battery longevity. The Company is also developing next generation solid state battery technology at its Labs division. Headquartered in Ontario, Canada, Electrovaya has two operating sites in Canada and has acquired a 52-acre site with a 135,000 square foot manufacturing facility in New York state for its planned gigafactory. To learn more about Electrovaya, please explore www.electrovaya.com.
SOURCE: Electrovaya, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Arvinas, Pfizer's Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment
Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in collaboration with Pfizer Inc. (NYSE:PFE), announced that the US FDA accepted its New Drug Application/NDA for vepdegestrant. The drug is intended to treat patients with estrogen receptor-positive/ER+, human epidermal growth factor receptor 2-negative/HER2-, ESR1-mutated advanced or metastatic breast cancer who have already received endocrine-based therapy. The FDA has set a Prescription Drug User Fee Act/PDUFA action date of June 5, 2026. The NDA is based on data from the Phase 3 VERITAC-2 clinical trial, which showed a statistically significant and clinically meaningful improvement in median progression-free survival for vepdegestrant compared to fulvestrant. The trial enrolled 624 patients at 213 sites across 25 countries, with 270 of these patients having the ESR1 mutation. A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. The results from this trial were recently presented at the American Society of Clinical Oncology/ASCO 2025 Annual Meeting and published in The New England Journal of Medicine. Vepdegestrant is an investigational oral drug that functions as a PROteolysis TArgeting Chimera/PROTAC estrogen receptor degrader. This marks the first time a PROTAC has demonstrated a clinical benefit in breast cancer patients. Arvinas Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. While we acknowledge the potential of ARVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Baird Reduces PT on lululemon athletica (LULU) Stock
lululemon athletica inc. (NASDAQ:LULU) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On August 11, Baird reduced the price objective on the company's stock to $260 from $340, keeping an 'Outperform' rating, as reported by The Fly. The firm updated the model after the recent selloff. In Q1 2025, lululemon athletica inc. (NASDAQ:LULU) saw growth throughout channels, categories, and markets, which include the US, reflecting the continued strength and agility of its business model. A store employee in an athletic apparel store restocking merchandise. lululemon athletica inc. (NASDAQ:LULU) added 3 net new company-operated stores during Q1 2025, ending with 770 stores. The company's gross margin came in at 58.3% in Q1 2025 as compared to 57.7% in Q1 2024. The rise was mainly because of a net increase in product margin of 110 bps, comprising a net increase of 130 bps due to reduced product costs and increased average unit retail, and lower damages, partially offset by elevated freight costs, and an unfavorable impact of foreign currency exchange rates of 20 bps. Diamond Hill Capital, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Other bottom contributors in Q1 included Lululemon athletica inc. (NASDAQ:LULU), General Motors and Capital One. Shares of athletic apparel manufacturer lululemon were pressured amid ongoing concerns about potential brand saturation in the Americas, its largest market. However, we believe the company is operating well and is positioned to improve US sales performance while continuing to grow international sales — factors that make the current valuation compelling, in our view.' While we acknowledge the potential of LULU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Citi Raised the Firm's PT on Expedia Group (EXPE), Kept a Neutral Rating
Expedia Group, Inc. (NASDAQ:EXPE) is one of the Undervalued Cyclical Stocks to Buy According to Hedge Funds. On August 13, Citi raised the firm's price target on Expedia Group, Inc. (NASDAQ:EXPE) from $177 to $206, while keeping a Neutral rating on the stock. The improved sentiment follows the company's strong second-quarter results for 2025. The company delivered $3.79 billion, up 6.41% year-over-year and ahead of estimates by $76.04 million. The EPS of $4.24 also beat expectations by $0.11. The analyst noted Expedia Group, Inc. (NASDAQ:EXPE) delivered better than expected results with gross bookings 2% above consensus, driven by a 7% increase in room nights. The firm also noted an improved demand from the US in July, which benefited the company. People interacting with a travel website, searching for the perfect destination. Expedia Group, Inc. (NASDAQ:EXPE) is an online travel company offering a wide range of travel services through consumer brands like Vrbo, and others. While we acknowledge the potential of EXPE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
